Relay Therapeutics (RLAY) Equity Ratio: 2020-2025
Historic Equity Ratio for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to 0.91.
- Relay Therapeutics' Equity Ratio rose 0.57% to 0.91 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91, marking a year-over-year increase of 0.57%. This contributed to the annual value of 0.89 for FY2024, which is 0.19% up from last year.
- Per Relay Therapeutics' latest filing, its Equity Ratio stood at 0.91 for Q3 2025, which was down 0.69% from 0.91 recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' Equity Ratio registered a high of 0.95 during Q1 2021, and its lowest value of 0.84 during Q2 2023.
- Its 3-year average for Equity Ratio is 0.88, with a median of 0.89 in 2023.
- Data for Relay Therapeutics' Equity Ratio shows a peak YoY increase of 233.69% (in 2021) and a maximum YoY decrease of 10.42% (in 2021) over the last 5 years.
- Relay Therapeutics' Equity Ratio (Quarterly) stood at 0.89 in 2021, then fell by 2.95% to 0.86 in 2022, then grew by 3.13% to 0.89 in 2023, then increased by 0.19% to 0.89 in 2024, then rose by 0.57% to 0.91 in 2025.
- Its last three reported values are 0.91 in Q3 2025, 0.91 for Q2 2025, and 0.90 during Q1 2025.